Antenatal corticosteroids (ACS) are commonly administered to pregnant women at risk of delivery before 34 weeks to enhance fetal lung development. Following the Antenatal Late Preterm Steroids (ALPS) trial in 2016, this practice was extended to mothers at risk of delivering in the late preterm period (34 0/7 to 36 6/7 weeks). However, corticosteroid use is known to predispose patients to infection. This study aims to investigate whether women given late preterm ACS at our center were at increased risk of chorioamnionitis or endometritis, or had prolonged postpartum hospitalizations.METHODS:
A retrospective chart review identified all LAC+USC patients who based on the ALPS trial were eligible for late preterm ACS between February 2015 and July 2017. Maternal outcomes were compared using Student’s t-test for continuous data and Pearson’s chi-squared test for categorical data. Significance was defined as a P-value <0.05.RESULTS:
Of 194 mothers found to eligible, 67 (34.5%) received ACS. The incidence of chorioamnionitis or endometritis was not significantly different between those who did and did not receive ACS, respectively (1.5% vs. 6.3%, p = 0.13). ACS recipients did not have significantly different postpartum length of stays compared to those who did not receive ACS (3.7 ± 1.1 vs. 3.7 ± 1.1 days, p = 0.88).CONCLUSION:
At LAC+USC, mothers who received late preterm ACS did not appear to experience greater risk of peripartum maternal infections, and ACS administration in the late preterm period did not appear to alter postpartum recovery time.